Litigation Details for NOVO NORDISK INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2017)
✉ Email this page to a colleague
NOVO NORDISK INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-05-11 |
| Court | District Court, D. New Jersey | Date Terminated | 2018-01-21 |
| Cause | 35:271 Patent Infringement | Assigned To | Michael Andre Shipp |
| Jury Demand | None | Referred To | Douglas Arpert |
| Patents | 7,018,992 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in NOVO NORDISK INC. v. GLENMARK PHARMACEUTICALS LIMITED
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for NOVO NORDISK INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-02-28 | 27 | alleged infringement of United States Patent No. 7,018,992 (“the ‘992 patent”). 3. Novo Nordisl<’s commencement…action and over the parties. 2. This action for patent infringement (the “Litigation”) was brought by …. § 355(])(2)(A)(vii)(I\/) directed to the ‘992 patent and seeking approval to market a generic version…2017 22 January 2018 3:17-cv-03462 830 Patent None District Court, D. New Jersey | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
